WithdrawnN/Aketamine

S Ketamine Use in Total Abdominal Hysterectomy

Sponsored by KK Women's and Children's Hospital

NCT ID
NCT02543385
Start Date
2014-06
Est. Completion
2015-06

About This Study

This study investigates the effect of low dose S+ketamine compared to placebo on cumulative morphine consumption at 24 hours in women undergoing open abdominal hysterectomy with remifentanil-propofol target controlled infusion. It compares the adverse effect profile in patients receiving S+ketamine as compared to those who did not. Participants are randomly distributed in two groups of 45 patient's each.

Conditions Studied

Total Abdominal Hysterectomy

Interventions

  • S Ketamine

Eligibility

Sex:FEMALE
Age:21 Years - 80 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Females above the age of 21 years old scheduled undergoing open abdominal hysterectomy with remifentanil-propofol TCI in KKH for benign condition (fibroids, adenomyosis),
* Be willing and able to give written informed consent for participation in this study
* ASA I/II patient's.

Exclusion Criteria:

* Patient with contraindications to the use of S+ketamine, as listed in the product label e.g. untreated or insufficiently treated thyroid hyperfunction, unstable angina pectoris or myocardial infarction within the last 6 months, diseases of the CNS, increased intraocular pressure and perforating ocular injuries, surgical procedures in the upper respiratory tract, etc
* Patients with a h/o drug or alcohol abuse
* Regular use of analgesics, or use of opioids within 12 hours of surgery
* Patient on chronic use of benzodiazepine or neurololeptics
* Patient on thyroid replacement hormone
* H/o IHD,HTN,Thyroid disorder.
* BMI\> 30kg/m2.
* H/o Psychiatric disorder.
* Laproscopic surgery converted to open surgery.
* Pregnant or breast feeding female's.

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source